Table 1.
Patient demographics.
| Total | Improved Group (VA increase ≥ 2 lines) | Unimproved Group (VA increase < 2 lines) | |
|---|---|---|---|
| Case number | 698 | 165 | 533 |
| Treatment-naïve (%) | 467 (66.91%) | 103 (62.42%) | 364 (68.29%) |
| Non-treatment-naïve (%) | 231 (33.09%) | 62 (37.58%) | 169 (31.71%) |
| Age years (± SD) | 78.47 ± 9.88 | 78.47 ± 9.88 | 83.28 ± 9.94 |
| Gender | |||
| Male (%) | 466 (66.76%) | 97 (58.79%) | 369(69.23%) |
| Female (%) | 232 (33.24%) | 68 (41.21%) | 164(30.77%) |
| Pre-therapeutic BCVA (mean ± SD) | 0.21 ± 0.16 | 0.32 ± 0.15 | 0.19 ± 0.15 |
| 12th month Post-therapeutic BCVA (mean ± SD) | 0.19 ± 0.19 | 0.62 ± 0.16 | 0.16 ± 0.16 |
| Anti-VEGF injections in 12 months (mean ± SD) | 4.19 ± 2.11 | 4.50 ± 2.15 | 4.18 ± 2.11 |
| Anti-VEGF agent | |||
| Aflibercept (%) | 544 (77.94%) | 134 (81.21%) | 410 (76.92%) |
| Ranibizumab (%) | 154 (22.06%) | 31 (18.79%) | 123 (23.08%) |